Krystal Biotech, Inc. (KRYS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers Krystal Biotech, Inc.'s quarterly report (Form 10-Q) for the period ended June 30, 2026. Krystal is a commercial-stage biotechnology company focused on genetic medicines using an engineered HSV-1 vector platform. Its primary commercial product is VYJUVEK (beremagene geperpavec-svdt), a gene therapy approved in the U.S., EU, UK, and Japan for the treatment of dystrophic epidermolysis bullosa (DEB). The company operates as a single segment and maintains two in-house commercial-scale manufacturing facilities.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Product Revenue, Net | $119,222 | $96,042 | $235,579 | $184,225 |
| Cost of Goods Sold | $6,437 | $7,165 | $12,760 | $12,193 |
| Gross Margin | 95% | 93% | 95% | 93% |
| Operating Expenses | $60,805 | $56,643 | $123,472 | $108,573 |
| Net Income | $54,768 | $38,333 | $110,700 | $74,067 |
| Diluted EPS | $1.79 | $1.29 | $3.62 | $2.48 |
| Cash & Short-Term Investments | $845.6 million (as of June 30, 2026) | |||
| Operating Cash Flow (YTD) | $155.2 million | $83.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 24% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 28% year-to-date. This growth was driven by international launches in Europe (Germany, France) and Japan, partially offset by a reduction in U.S. sales.
- Profitability Expansion: Net income rose 43% in Q2 and 49% YTD. Operating income increased 48% in both periods due to revenue growth outpacing expense increases.
- Expense Trends: Selling, General, and Administrative (SG&A) expenses increased 14% in Q2 and 19% YTD, driven by higher payroll, travel, and commercialization costs. Research and Development (R&D) expenses remained relatively flat in Q2 (+1%) but increased 4% YTD, with specific increases in programs KB801, KB803, and KB407.
- Liquidity: Cash and cash equivalents decreased to $427.7 million from $496.3 million at year-end 2025, while short-term and long-term investments increased significantly. Total cash and investments remain robust at $845.6 million.
Guidance, Outlook, and Risks
- Commercial Outlook: Management expects to fund operations for at least the next 12 months using current cash and VYJUVEK revenue. Pricing negotiations are ongoing in Germany and France (expected to continue through late 2026/2027). Launches in Italy and Spain are targeted for the second half of 2026.
- Pipeline Milestones:
- KB803 (Ocular DEB): Enrollment in the Phase 3 IOLITE study completed; top-line results expected before year-end 2026.
- KB801 (Neurotrophic Keratitis): Enrollment in the EMERALD-1 registrational study is ongoing, expected to complete by year-end.
- KB407 (Cystic Fibrosis): Interim results from the repeat-dose study expected before year-end; registrational study design anticipated in H2 2026 with initiation in 2027.
- KB707 (Oncology): Interim results for inhaled KB707 in combination with chemotherapy expected in H1 2027.
- Risks and Contingencies:
- Legal Proceedings: The company is cooperating with a U.S. Department of Justice inquiry regarding its sponsored genetic testing program; potential loss is not estimable. A derivative lawsuit regarding director compensation has reached a settlement pending court approval. A patent inventorship lawsuit regarding KB407 was filed in May 2026; the company intends to defend vigorously.
- Regulatory & Market Access: Future revenue is subject to pricing negotiations and reimbursement approvals in international markets. Clinical trial outcomes for pipeline candidates remain uncertain.
Investor Verification Checklist
- International Revenue Mix: Verify the sustainability of revenue growth from new EU and Japan launches versus the decline in U.S. sales.
- Rebate Accruals: Review the significant increase in accrued rebates (from $58.2M to $83.5M) and its impact on net revenue recognition.
- Legal Exposure: Monitor the status of the DOJ inquiry and the patent litigation regarding KB407 for potential financial or operational impacts.
- Cash Burn vs. Generation: Confirm that operating cash flow generation ($155M YTD) continues to offset capital expenditures and investment purchases to maintain the $845M liquidity position.
- Pipeline Data Readouts: Track the timing and results of the KB803 (IOLITE) and KB407 interim data releases expected in late 2026.